World Trade Flash

An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?

An Alzheimer’s Drug Could Supercharge This High-Risk Stock. Is It Worth a Buy Here?

vTv Therapeutics (VTVT) is a $156 million biopharma focused on small molecule drugs for Alzheimer’s, diabetes, and inflammatory disorders, all in clinical trials. VTVT has surged 182% over the past year, hitting a two-year high, with strong technical...

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
INFINITY AI
Instagram Meta X LinkedIn Whatsapp